Back to top
more

Entera Bio (ENTX)

(Delayed Data from NSDQ)

$3.47 USD

3.47
429,945

+0.05 (1.46%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $3.48 +0.01 (0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Entera Bio Ltd. (ENTX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Entera Bio Ltd. (ENTX) closed the most recent trading day at $0.91, moving +1.11% from the previous trading session.

Zacks Equity Research

Entera Bio Ltd. (ENTX) Flat As Market Gains: What You Should Know

by Zacks Equity Research

Entera Bio Ltd. (ENTX) closed at $0.95 in the latest trading session, marking no change from the prior day.

Zacks Equity Research

Entera Bio Ltd. (ENTX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Entera Bio Ltd. (ENTX) closed at $0.90 in the latest trading session, marking a -1% move from the prior day.

Zacks Equity Research

Entera Bio Ltd. (ENTX) Flat As Market Sinks: What You Should Know

by Zacks Equity Research

In the latest trading session, Entera Bio Ltd. (ENTX) closed at $0.95, marking no change from the previous day.

Zacks Equity Research

Entera Bio Ltd. (ENTX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Entera Bio Ltd. (ENTX) closed at $0.88, marking a +1.87% move from the previous day.

Zacks Equity Research

New Strong Buy Stocks for December 29th

by Zacks Equity Research

SPNS, CRS, DHT, DCBO and ENTX have been added to the Zacks Rank #1 (Strong Buy) List on December 29, 2022.

Zacks Equity Research

New Strong Buy Stocks for November 21st

by Zacks Equity Research

AMRK, ACR, EDAP, H and ENTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2022.

Zacks Equity Research

Ardelyx (ARDX) Up 41% After FDA Committee Endorses CKD Drug

by Zacks Equity Research

The FDA's CRDAC recommends granting marketing approval to Ardelyx's (ARDX) oral pill to control serum phosphorus in adult patients with chronic kidney disease on dialysis.

Zacks Equity Research

4D Molecular (FDMT) Stock Up 178% in One Month: Here's Why

by Zacks Equity Research

4D Molecular's (FDMT) progress with the development of its pipeline candidates in cystic fibrosis and wet AMD indications have been significant catalysts for the stock.

Zacks Equity Research

Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down

by Zacks Equity Research

Due to discontinuing the development of its lead candidate, Neoleukin (NLTX) has no pipeline candidates in clinical development. Management undertakes restructuring initiatives to curb cash burn.